<DOC>
	<DOCNO>NCT03097666</DOCNO>
	<brief_summary>The primary objective determine safety efficacy C2 CryoBalloon™ Swipe Ablation System ( `` CryoBalloon Swipe '' ) use increase dos .</brief_summary>
	<brief_title>Evaluation Safety Dose Response Using C2 CryoBalloon™ Swipe Ablation System Barrett 's Esophagus</brief_title>
	<detailed_description>The procedure perform outpatient basis accord site standard care anesthesia sedation esophagogastroduodenoscopy ( EGD ) procedure . The CryoBalloon Swipe use ablation , follow instruction use provided product . Patients meet eligibility criterion assign one treatment group dos , depend order enrollment : Phase I The first two patient ( subject 1-2 ) treat Dose 1 ( low ) . As many application need ablate 50 % esophageal circumference do . If Dose-related SAE within seven ( 7 ) day post-treatment , another four ( 4 ) patient ( subject 3-6 ) treat fashion , total 6 patient treat Dose 1 . All patient undergo 8 week ( ±1 week ) follow-up EGD evaluate efficacy dose study continue . If follow-up endoscopy show Dose 1 eradicates ≥80 % treat BE ( median percentage 6 patient base EGD-Adjudication Committee evaluation ) , SAE 's report , dose define therapeutic dose enrollment proceed phase II . If Dose 1 eradicates &lt; 80 % treat BE ( median percentage treat patient assess EGD-Adjudication Committee ) , enrollment Phase I continue 0.1mm/sec increase dose ( 0.7mm/sec ; Second Dose ) . Treatment dos escalate manner earlier dose-related Serious Adverse Event ( SAE ) determination therapeutic dose base endoscopic exam biopsy . When therapeutic dose determine , study proceed Phase II generate additional safety efficacy data . Phase II Phase II confirm safety efficacy therapeutic dose find Phase I. Twelve ( 12 ) subject ienrolled . As many application need ablate 50 % circumference 3cm length BE do use efficacious dose determine Phase I . The subject return endoscopic exam eight ( 8 ) week post-index procedure ( ±1 week ) , time untreated ( contralateral ) portion target segment ablate . -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- - Dose-related SAEs include pain treatment area great 6 ( VAS ) 24 hour seven ( 7 ) day post-treatment ; symptomatic stricture require additional EGD endoscopic dilation first follow-up EGD ; symptomatic stricture follow-up EGD ; stricture ( symptomatic asymptomatic ) prevent passage diagnostic endoscope follow-up EGD . Any serious adverse event within 30 day treatment also evaluate Data Safety Monitoring Board ( DSMB ) relationship dose severity . When Dose-related serious adverse event occur , Holding Rule invoke enrollment dose hold DSMB evaluate event .</detailed_description>
	<mesh_term>Barrett Esophagus</mesh_term>
	<criteria>1 . Patients flattype ( Paris type 0IIb ) BE esophagus , indication ablation therapy , meaning : Diagnosis LGD HGD BE ( confirm baseline histopathological analysis ) , OR Residual BE grade dysplasia endoscopic resection 2 . Prague Classification Score C≤3 3 . Patients ablativenaïve ( previous ablation therapy esophagus ) 4 . Older 18 year age time consent 5 . Operable per institution 's standard 6 . Provides write informed consent IRBapproved inform consent form 7 . Willing able comply followup requirement 1 . Esophageal stenosis stricture prevent advancement therapeutic endoscope . 2 . Any endoscopically visualize lesion ulcer , mass nodule . 3 . History locally advance ( &gt; T1a ) esophageal cancer 4 . History esophageal varix 5 . Prior distal esophagectomy 6 . Active esophagitis LA grade B high 7 . Severe medical comorbidities preclude endoscopy 8 . Uncontrolled coagulopathy 9 . Pregnant plan become pregnant period study 10 . Patient refuse unable provide write informed consent 11 . Participation another study investigational drug within 30 day precede present study 12 . General poor health , multiple comorbidities place patient risk otherwise unsuitable trial participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>